Literature DB >> 2117162

The epidemiology of alpha 1-antitrypsin deficiency.

D C Hutchison1.   

Abstract

Alpha 1-protease inhibitor can exist as over 70 different biochemical variants (the Pi system) which are inherited as autosomal-codominant alleles. The majority of these variants are of no clinical significance. Epidemiologically, the most abundant are Pi types M, S, and Z. Homozygotes of type Z have only 10%-20% of the normal serum concentration of the inhibitor and have an increased risk of developing pulmonary emphysema. Cigarette smoking is the most important risk factor. A minority of Pi Z homozygotes (10%-20%) develop a form of neonatal hepatitis and a proportion of these suffer from liver cirrhosis in adult life. Heterozygotes of Pi type SZ have about one third of the normal serum alpha 1-protease inhibitor concentration but this phenotype does not in itself appear to be a significant emphysema risk factor. Heterozygotes of Pi type MZ are thought to have a moderately increased risk of developing emphysema but only if they smoke; there is also evidence for an increased risk of cirrhosis among subjects of type MZ. No excessive risk appears to be attached to the MS phenotype. Cumulative survival curves have suggested that type Z homozygotes have a poor prognosis but such estimates are based on clinic or hospital patients who already have respiratory symptoms. Calculations based on population frequencies however, suggest that about 90% of the total number of type Z subjects are not accounted for in such surveys. Their whereabouts remains unclear at present; some will undoubtedly have died of liver or lung disease but it is possible that the majority escape and live undetected among the general population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117162     DOI: 10.1007/bf02718176

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  37 in total

1.  Antitrypsin phenotypes in St. Louis.

Authors:  J A Pierce; B Eradio; T A Dew
Journal:  JAMA       Date:  1975-02-10       Impact factor: 56.272

2.  The PiMZ phenotype: is it a significant risk factor for the development of chronic obstructive lung disease?

Authors:  C Mittman
Journal:  Am Rev Respir Dis       Date:  1978-10

3.  1 -Antitrypsin deficiency: a variant with no detectable 1 -antitrypsin.

Authors:  R C Talamo; C E Langley; C E Reed; S Makino
Journal:  Science       Date:  1973-07-06       Impact factor: 47.728

4.  Serum alpha 1-antitrypsin in bronchial asthma.

Authors:  A Szczeklik; B Turowska; G Czerniawska-Mysik; B Opolska; E Nizankowska
Journal:  Am Rev Respir Dis       Date:  1974-04

5.  Report of Nomenclature Meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978.

Authors:  D W Cox; A M Johnson; M K Fagerhol
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

6.  alpha1-Antitrypsin deficiency in nonsmokers.

Authors:  L F Black; F Kueppers
Journal:  Am Rev Respir Dis       Date:  1978-03

7.  Serum alpha 1-antitrypsin variants. Prevalence and clinical spirometry.

Authors:  D R Webb; R W Hyde; R H Schwartz; W J Hall; J J Condemi; P L Townes
Journal:  Am Rev Respir Dis       Date:  1973-10

8.  Alpha 1-antitrypsin deficiency: the radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association.

Authors:  P Gishen; A J Saunders; M J Tobin; D C Hutchison
Journal:  Clin Radiol       Date:  1982-07       Impact factor: 2.350

9.  Pulmonary function associated with the Mmalton deficient variant of alpha 1-antitrypsin.

Authors:  B J Sproule; D W Cox; K Hsu; M L Salkie; F A Herbert
Journal:  Am Rev Respir Dis       Date:  1983-02

10.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.

Authors:  M J Tobin; P J Cook; D C Hutchison
Journal:  Br J Dis Chest       Date:  1983-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.